Constitutive activation of the mTOR signaling pathway within the normal glomerulus

Biochemical and Biophysical Research Communications

Volumn 425, Issue 2, 2012, Pages 244-249

  McMahon, Gearoid M ^a,b   Datta, Dipak ^a,b   Bruneau, Sarah ^a,b   Kann, Martin ^a,b   Khalid, Myda ^a,b   Ho, Jacqueline ^a,b   Seto, Tatsuichiro ^a,b   Kreidberg, Jordan A ^a,b   Stillman, Isaac E ^b   Briscoe, David M ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glomerulus; Kidney; MTOR; Podocyte; Signaling

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NEPHRIN; RAPAMYCIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL GROWTH; CELL ISOLATION; CELL TYPE; CONTROLLED STUDY; DRUG TARGETING; GLOMERULUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; KIDNEY INTERSTITIUM; KIDNEY TUBULE CELL; MAGNETIC BEAD; MAGNETIC FIELD; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING;

ANIMALS; FLUORESCENT ANTIBODY TECHNIQUE; HOMEOSTASIS; HUMANS; KIDNEY GLOMERULUS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; PODOCYTES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MAMMALIA; MUS;

EID: 84865367034     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.075     Document Type: Article

References (36)

1. Dazert E., Hall M.N. MTOR signaling in disease. Curr. Opin. Cell Biol. 2011, 23:744-755.
2. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005, 17:596-603.
3. Zoncu R., Efeyan A., Sabatini D.M. MTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
4. Hall M.N. MTOR-what does it do?. Transplant. Proc. 2008, 40:S5-S8.
5. Su B., Jacinto E. Mammalian TOR signaling to the AGC kinases. Crit. Rev. Biochem. Mol. Biol. 2011, 46:527-547.
6. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
7. Facchinetti V., Ouyang W., Wei H., Soto N., Lazorchak A., Gould C., Lowry C., Newton A.C., Mao Y., Miao R.Q., Sessa W.C., Qin J., Zhang P., Su B., Jacinto E. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008, 27:1932-1943.
8. Howell J.J., Manning B.D. MTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol. Metab. 2011, 22:94-102.
9. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 2003, 35:7S-14S.
10. Contreras A.G., Dormond O., Edelbauer M., Calzadilla K., Hoerning A., Pal S., Briscoe D.M. MTOR-understanding the clinical effects. Transplant. Proc. 2008, 40:S9-S12.
11. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
12. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
13. Mondino A., Mueller D.L. MTOR at the crossroads of T cell proliferation and tolerance. Semin. Immunol. 2007, 19:162-172.
14. Dormond O., Madsen J.C., Briscoe D.M. The Effects of mTOR-Akt Interactions on Anti-apoptotic Signaling in Vascular Endothelial Cells. J. Biol. Chem. 2007, 282:23679-23686.
15. Fogo A.B. The targeted podocyte. J. Clin. Invest. 2011, 121:2142-2145.
16. Walid S., Eisen R., Ratcliffe D.R., Dai K., Hussain M.M., Ojakian G.K. The PI 3-kinase and mTOR signaling pathways are important modulators of epithelial tubule formation. J. Cell. Physiol. 2008, 216:469-479.
17. Wahl P.R., Le Hir M., Vogetseder A., Arcaro A., Starke A., Waeckerle-Men Y., Serra A.L., Wuthrich R.P. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology (Carlton) 2007, 12:357-363.
18. Edelstein C.L. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clinical journal of the American Society of Nephrology: CJASN 2008, 3:1219-1226.
19. Walz G., Budde K., Mannaa M., Nurnberger J., Wanner C., Sommerer C., Kunzendorf U., Banas B., Horl W.H., Obermuller N., Arns W., Pavenstadt H., Gaedeke J., Buchert M., May C., Gschaidmeier H., Kramer S., Eckardt K.U. Everolimus in patients with autosomal dominant polycystic kidney disease. The New England journal of medicine 2010, 363:830-840.
20. Perico N., Antiga L., Caroli A., Ruggenenti P., Fasolini G., Cafaro M., Ondei P., Rubis N., Diadei O., Gherardi G., Prandini S., Panozo A., Bravo R.F., Carminati S., De Leon F.R., Gaspari F., Cortinovis M., Motterlini N., Ene-Iordache B., Remuzzi A., Remuzzi G. Sirolimus therapy to halt the progression of ADPKD. Journal of the American Society of Nephrology: JASN 2010, 21:1031-1040.
21. Serra A.L., Poster D., Kistler A.D., Krauer F., Raina S., Young J., Rentsch K.M., Spanaus K.S., Senn O., Kristanto P., Scheffel H., Weishaupt D., Wuthrich R.P. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. The New England journal of medicine 2010, 363:820-829.
22. Kumar D., Konkimalla S., Yadav A., Sataranatarajan K., Kasinath B.S., Chander P.N., Singhal P.C. HIV-associated nephropathy: role of mammalian target of rapamycin pathway. The American journal of pathology 2010, 177:813-821.
23. Budde K., Gaedeke J. Tuberous Sclerosis Complex-Associated Angiomyolipomas: Focus on mTOR Inhibition. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 2011, 59:276-283.
24. Takemoto M., Asker N., Gerhardt H., Lundkvist A., Johansson B.R., Saito Y., Betsholtz C. A new method for large scale isolation of kidney glomeruli from mice. Am. J. Pathol. 2002, 161:799-805.
25. Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., Sun J., Monahan-Earley R.A., Shiojima I., Nagy J.A., Lin M.I., Walsh K., Dvorak A.M., Briscoe D.M., Neeman M., Sessa W.C., Dvorak H.F., Benjamin L.E. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006, 10:159-170.
26. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
27. Dormond O., Contreras A.G., Meijer E., Datta D., Flynn E., Pal S., Briscoe D.M. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J. Immunol. 2008, 181:8088-8095.
28. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
29. El-Hashemite N., Walker V., Zhang H., Kwiatkowski D.J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 2003, 63:5173-5177.
30. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22:7004-7014.
31. Sison K., Eremina V., Baelde H., Min W., Hirashima M., Fantus I.G., Quaggin S.E. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J. Am. Soc. Nephrol. 2010, 21:1691-1701.
32. Eremina V., Baelde H.J., Quaggin S.E. Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol. 2007, 106:32-37.
33. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.P., Kikkawa Y., Miner J.H., Quaggin S.E. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003, 111:707-716.
34. Inoki K., Mori H., Wang J., Suzuki T., Hong S., Yoshida S., Blattner S.M., Ikenoue T., Ruegg M.A., Hall M.N., Kwiatkowski D.J., Rastaldi M.P., Huber T.B., Kretzler M., Holzman L.B., Wiggins R.C., Guan K.L. MTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 2011, 121:2181-2196.
35. Godel M., Hartleben B., Herbach N., Liu S., Zschiedrich S., Lu S., Debreczeni-Mor A., Lindenmeyer M.T., Rastaldi M.P., Hartleben G., Wiech T., Fornoni A., Nelson R.G., Kretzler M., Wanke R., Pavenstadt H., Kerjaschki D., Cohen C.D., Hall M.N., Ruegg M.A., Inoki K., Walz G., Huber T.B. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J. Clin. Invest. 2011, 121:2197-2209.
36. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.